Beigene Ltd (ADRs) (BGNE.xnas) is a biotechnology company headquartered in Beijing, China. Beigene specialises in the development of drugs for cancer treatment. Its products include tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton’s tyrosine kinase inhibitor, which became the 1st cancer drug developed in China to gain approval from the U.S Food and Drug Administration. Beigene has offices in China, Australia, the United States and Europe and employs approximately 3,500 people worldwide. Beigene Ltd stock is listed on the NASDAQ and had a market capitalisation of $26.59B (USD) as of January 2022 and $1.11B (USD) in 2021 yearly revenues. At the end of 2021, the company announced an option, collaboration and licence agreement with Novartis Pharma AG to develop, manufacture and commercialise Beigene’s investigational TIGIT inhibitor ociperlimab in Europe, North America, and Japan. Additionally, both companies entered into an agreement granting Beigene rights to market, promote and detail five approved Novartis oncology products across designated regions of China. The European Commission (EC) approved Beigene’s drug BRUKINSA to treat adult patients with Waldenstrom’s macroglobulinemia (WM).
Beigene Ltd (ADRs) (BGNE)
Explore Beigene Ltd (ADRs) (BGNE) share price insights and trends to guide your investment strategy. Stay informed with FP Markets Kenya.